Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

(2017) Nicolas Mottet et al.   EUROPEAN UROLOGY

Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study

(2017) Bertrand Tombal et al.   JOURNAL OF UROLOGY

Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer

(2016) Jürgen Breul et al.   ADVANCES IN THERAPY

Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer

(2016) Neal D. Shore et al.   BJU INTERNATIONAL

Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy

(2016) Alexandre de la Taille et al.   BJU INTERNATIONAL

A randomized controlled trial to determine the effect of triptorelin on reduction of prostate volume preradiotherapy compared with standard therapy (goserelin).

(2016) Amit Bahl et al.   JOURNAL OF CLINICAL ONCOLOGY

Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

(2016) Lesley Uttley et al.   PHARMACOECONOMICS

Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer

(2016) Satoshi WASHINO et al.   LUTS-Lower Urinary Tract Symptoms

Degarelix versus Goserelin plus Bicalutamide Therapy for Lower Urinary Tract Symptom Relief, Prostate Volume Reduction and Quality of Life Improvement in Men with Prostate Cancer: A Systematic Review and Meta-Analysis

(2014) Yuanshan Cui et al.   UROLOGIA INTERNATIONALIS

Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists

(2013) Jun Kawakami et al.   CUAJ-Canadian Urological Association Journal

Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case

(2013) Tsung-Yi Huang et al.   World Journal of Surgical Oncology

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide

(2012) Karol Axcrona et al.   BJU INTERNATIONAL

Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?

(2012) Tom Pickles et al.   BJU INTERNATIONAL

Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus Bicalutamide

(2012) M. Mason et al.   CLINICAL ONCOLOGY

Triptorelin in the management of prostate cancer

(2012) Guillaume Ploussard et al.   Future Oncology

Goserelin versus leuprolide in the chemical castration of patients with prostate cancer

(2012) Élcio Dias Silva et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort

(2011) E. David Crawford   Cancer Management and Research

Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer

(2009) Eija A. Lundström et al.   CLINICAL DRUG INVESTIGATION

Granulomas induced by subcutaneous injection of a luteinizing hormone-releasing hormone analog: a case report and review of the literature

(2009) Tessin Watanabe et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Duration of Androgen Suppression in the Treatment of Prostate Cancer

(2009) Michel Bolla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of advanced prostate cancer: can we improve on androgen deprivation therapy?

(2008) John Anderson et al.   BJU INTERNATIONAL

Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer

(2008) Yasuhisa Fujii et al.   BJU INTERNATIONAL

Quality of Life, Morbidity, and Mortality Results of a Prospective Phase II Study of Intermittent Androgen Suppression for Men with Evidence of Prostate-Specific Antigen Relapse After Radiation Therapy for Locally Advanced Prostate Cancer

(2008) Nicholas Bruchovsky et al.   Clinical Genitourinary Cancer

Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31

(2008) Jason A. Efstathiou et al.   JOURNAL OF CLINICAL ONCOLOGY